rev profit order momentum slow
reduc price target slightli
top line varian deliv revenu million versu estim
million consensu estim million oncolog system
revenu million versu estim million proton
solut segment fell short expect deliv million
revenu versu estim million gross oncolog system order
quarter increas report constant currenc proton
solut busi final broke sever quarter dri spell
receiv three order quarter total million revenu
bottom line varian report non-gaap ep figur quarter
versu expect consensu estim strong
revenu better-than-expect gross margin solid expens manag
primari catalyst profit beat
balanc sheet cash flow varian end quarter cash
equival approxim million million debt
associ recent flow oper quarter
million million versu period last year
outlook varian financi guidanc includ assumpt
revenu growth revenu growth previous non-gaap
ep rang vs prior guidanc cash flow
oper rang million previou rang
million non-gaap effect tax rate expect
weight averag share count around million
slightli reduc non-gaap ep estim
recommend maintain outperform invest rate
share slightli lower price target arriv
price target attach multipl adjust ebitda estim
assum million net cash month
revenu mil estimate bold
ep estimate bold
upsid price
return equiti ltm
note pleas refer page end
report import disclosur
overal varian deliv strong revenu profit fiscal third quarter
order momentum slow fairli significantli fair varian order momentum
past sever quarter excel quarter result set
difficult comparison varian manag also provid updat compani
financi guidanc includ higher revenu expect narrow rang
adjust ep somewhat lower oper cash flow
revenu look revenu oper segment oncolog system revenu came
million well million estim revenu
segment increas around versu compar period last year product
revenu growth whop quarter servic increas
varian proton solut segment deliv million revenu declin around
versu compar quarter last year estim busi
gross margin oper expens total consolid gross margin came
versu estim non-gaap gross margin
decreas bp versu last year compar quarter tariff headwind
unfavor mix primari reason neg comparison oncolog
deliv gross margin repres neg comparison bp
sg expens came revenu expect non-
sg expens bp yoy expens
revenu versu model
profit non-gaap ep came easili beat estim
well consensu expect
balanc sheet cash flow varian end quarter cash equival
approxim million million debt flow
oper million quarter
varian report strong revenu profit quarter order momentum
slow meaning tough comparison year ago manag
updat guidanc includ bullish revenu outlook surpris given
strong order growth past month plu recent narrow ep rang
reduct cash flow oper
varian financi guidanc includ expect overal
revenu growth increas previou revenu growth guid
non-gaap ep vs prior rang non-gaap oper margin
rang oper cash flow
million current model non-gaap ep
revenu growth previou non-gaap ep expect
despit somewhat disappoint order result quarter varian believ
continu captur market share radiat therapi market estim
grow around manag believ compani willing invest
innov expand compet via allow continu push
boundari current market share
quarter oncolog system revenu increas whop despit
bp neg impact tariff activ excel result broad-bas
includ revenu growth america region addit emea region
show revenu growth report grew constant currenc final
asia-pacif region grew revenu report constant currenc
oncolog system order grew report dollar constant
currenc meaning slowdown order momentum recent quarter
result face difficult year-over-year comparison addit even given
somewhat soft result quarter gross order trail month still
dollar constant currenc
america gross oncolog order million declin
europ middl east india africa region gross oncolog order increas
dollar million constant currenc region
consecut double-digit growth perform constant currenc final gross
oncolog order asia-pacif region million
dollar increas constant currenc china cite posit
region demonstr strong double-digit growth quarter despit tariff nois
compani net instal base unit increas versu
period last year
compani gener addit halcyon order quarter bring
total sinc product first unveil vienna may global
instal base halcyon system stand
varian continu see strong demand softwar solut softwar
revenu increas quarter hardwar also show strong growth
quarter final servic revenu
varian proton solut busi gener million revenu
quarter book three new order total million five quarter
without new proton order quarter recaptur momentum certainli
encourag less sunni note compani forc take
goodwil impair charg busi time total million
despit quarter order worth note margin proton solut
segment well compani averag expect remain
forese futur said compani state remain commit
busi highlight potenti revolutionari flash technolog among
reason compani would continu invest area
remind varian new flash technolog shown earli pre-clin
work promis amazingli quick treatment throughput attack cancer
tumor larg spare healthi tissu trial could begin within month
believ initi could ultim success result genuin paradigm
shift radiat therapi space
compani activ pursu expans footprint via
extern growth continu express high enthusiasm recent
effort includ cyberheart v-tach market endocar boston
scientif microspher embol bead product endocar
contribut million aggreg revenu quarter
compani believ pois help custom implement value-
base care continu shift toward value-bas model detail
regard price coverag area variou implic transit
certainli better understood later year
though somewhat difficult predict term time certain expect
increment order varian continu bullish regard growth prospect
china india next two three year beyond
varian continu activ share repurchas activ repurchas
approxim million share quarter compani still
million share remain current share repurchas author quarter end
maintain outperform invest rate share slightli
reduc price target arriv price target attach
multipl adjust ebitda estim assum million
net cash month
revenu
interest incom net
 revenu
sg revenu
pre-shar repo chg wc
million except per share data
 xp ec ted ut pe th rke xt th
 xp ec ted rfo rm ro ly th ke th ne nth
lo -te te nti xi ts bu ne -te rm ca ta ly
 xp ec ted de er fo rm th rk et er xt th
co ny fu ta ls de te ri ra tin
fu lli va lu ov r- va lu cu le ls
 lo rice ta ge fo thi co pa se /e da th ho
ri ks th ta rg ri ce ch ie clu ut ot im ite failu
co ar stim te
th fo wi ng li ra tin fo co pa ie co rr ton ea ch cia te
inc ju er om ie ate tp fo
 se te co ni es th ov ra list th um co pa ie ate
 rf rm es nte co nie th co ag list
th um co ni ra te un rp fo wa se te al
co mp ie th ov er list lso un rri gto se rch cia te
inc ov id stm en kin se rv ice ith th la st th
co pa es th tp ra tin th co ni th ha
 rf orm ti gs th co es th ha nd rf rm
na ly er tific ion se rc na lyst sp ns ib le fo th ra tio th es ea ch po ich tu sk fa eb ce rti fi
th vi ws ut th om ie nd th eir se cu iti xp ss th rt ccu ate ly fle ct hi er op ni ns lyst lso
ce rtifi th rt hi co pe sa ti dire ctl ir ctli el te th pe cific co mm ati vie co ta th rt
 es ea ch lyst cl di th os vo lv ed th ep ati thi rt ce ive ct om sa tio co ne cti wi th th firm
stm nk ctiviti ly st co ns ati wh ich sa la nu ba se us fa cto rs clu
sto ck pr ice rfo ce al iti al ysi nv sto cl ie fee ck th al ro fita il iti th fi rm wh ich mp cte
 th firm us ss cti viti clud ng th th titutio na qu iti tr nv es tme nk se rvi ce
stm en kin se vic es de fi ne le clu es th thi gs ac tin un wri ter
 lli gr se cu riti rw riti al yst sp si le fo th rt ae tu sk fa em th lyst
 us eh ld sh th co sto ck th co pa la tio te le th ro ib se rc yst
fro tra se cu ri tie co co du sp ec ifi tim er io nd fte th pu li ca tio es rch ep rt
 rr ton se rch cia te fu ll-se vic fina ci al se vic es firm th ffe rs wid va ie ty se vic es nd pr du ts lie ts
sto rs sh ld ass tha rr ton ea ch ee ill se stm kin th us ss la ti sh ip ith th
co es ts se rc co er rin se rc ce iv ed nve tme ki g- ate co en sa tio fro thi
co ith th pa st nth xp ct wi th th xt th mo th
barrington research associ inc finra-regist broker/deal clear wedbush secur fulli
disclos basi conveni client offer sever way client facilit payment
trade barrington research order may place trade desk
trader michael hutchison head trader christoph pari email address
instant messeng address brrrmh
trade broker trade may also stepped-in barrington research trade execut broker
commiss share arrang barrington commiss share agreement numer broker wall
street complet list commiss share program barrington research particip pleas contact
salesperson trade desk
follow list provid barrington research trade alloc settlement id wedbush dtc code
question trade set account relat inform pleas call trade depart
inform contain herein obtain sourc believ reliabl guarante accuraci complet
opinion estim reflect best judgment report date subject chang without notic report intend inform
purpos constitut offer solicit buy sell secur barrington research associ inc affili offic
analyst employe may time time posit secur refer herein barrington research associ inc may act
princip agent buyer seller purchas sale secur mention report barrington research associ
inc may provid may seek provid invest bank servic compani mention report report may
reproduc form without prior written consent barrington research associ inc right reserv member finra/sipc
